한글목차

세계의 혈장 분획 시장 규모는 예측 기간 중 CAGR로 9.1%의 건전한 성장이 예측됩니다.

지역의 인사이트

북미 시장이 2022년에 최대 시장 점유율을 차지했습니다. 이것은 다양한 유전성 질환의 유행, 노년 인구의 증가, 지역에서 의료 이용의 확대에 의한 것입니다. 유럽 시장은 지역에서 면역부전과 소모성 질환의 우위성 증가 및 이 프레임워크에 대한 관심의 확대에 의해 2번째로 큰 시장 점유율을 차지하고 있습니다.

중동 및 아프리카·라틴아메리카 시장은 지역에서 면역계 질환의 유행에 의해 발전을 보일 전망입니다.

세계의 혈장 분획 시장에 대해 조사분석했으며, 시장 역학, 지역과 부문 분석, 기업 개요 등을 제공하고 있습니다.

목차

제1장 주요 요약

• 세계의 혈장 분획 시장 : 제품 유형별
• 세계의 혈장 분획 시장 : 용도별
• 세계의 혈장 분획 시장 : 최종사용자별
• 세계의 혈장 분획 시장 : 지역별

제2장 시장의 서론

제3장 조사 방법

제4장 시장 역학

• 촉진요인
  • 다양한 치료 분야에서 면역글로불린의 사용 증가
  • 혈장분획 제재에 대한 수요가 시장 성장을 촉진
  • 촉진요인의 영향 분석
• 억제요인
  • 혈장분획 제재의 대체로서 재조합 요법의 부상이 시장 성장을 억제
  • 억제요인의 영향 분석
• 기회
  • 시장 성장을 촉진하는 주요 기업에 의한 신기술 발표

제5장 시장 요인 분석

• 공급망 분석
• Porter's Five Forces 모델
• 혈장 분획 시장에서 주요 콜드체인 제품/디바이스
• 세계의 혈장 분획 시장에 대한 COVID-19의 영향
  • 공급망에 대한 영향
  • 생산에 대한 영향
  • 지역에 대한 영향
  • 수급 격차에 대한 영향 분석
  • 가격에 대한 영향

제6장 세계의 혈장 분획 시장 : 제품 유형별

• 개요
• 면역글로불린
  • 정맥주사용 면역글로불린
  • 피하주사용 면역글로불린
  • 기타
• 농축 응고인자
  • 제VIII인자
  • 제IX인자
  • 폰빌레브란트인자
  • 농축 프로트롬빈 복합체
  • 농축 피브리노겐
  • 제XIII인자
• 알부민
• 프로테아제 저해제
• 기타

제7장 세계의 혈장 분획 시장 : 용도별

• 개요
• 면역
• 신경
• 혈액
• 중환자치료
• 호흡기
• 류마티스
• 혈액 종양
• 기타

제8장 세계의 혈장 분획 시장 : 최종사용자별

• 개요
• 병원·진료소
• 임상 연구기관
• 학술기관
• 기타

제9장 세계의 혈장 분획 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 기타 지역
  • 라틴아메리카
  • 중동
  • 아프리카

제10장 경쟁 구도

• 경쟁의 개요
• 세계의 혈장 분획 시장에서 주요 성장 전략
• 경쟁 벤치마킹

제11장 기업 개요

• CSL BEHRING
• GRIFOLS THERAPEUTICS
• BAXTER INTERNATIONAL INC.
• MITSUBISHI TANABE
• TAKEDA PHARMACEUTICAL
• OCTAPHARMA AG
• HUALAN BIO
• KEDRION S.P.A
• LFB GROUP
• BIOTEST AG

영문목차

Market Overview

The Plasma Fractionation Market is expected to register a healthy CAGR of 9.1% during the forecast period. The creating use of immunoglobulins for various supportive regions and interest in plasma-deduced restorative things drive the market advancement driving market improvement.

Immunoglobulins are used as first-line treatment for various neurologic, immunologic, and hematologic conditions. To some degree as of late, the finding speed of various immunological diseases has extended in view of mechanical types of progress. The creation inherited assessment for portraying and diagnosing immunodeficiency will similarly extend the clinical necessity for immunoglobulins in view of the extended number of dissected patients. Moreover, the inescapability of unprecedented and safe framework diseases and an extension in immunology research by and large are further driving the advancement of this part. According to data circulated by the Public Spot for Advancing Translational Sciences in February 2022, there are about 7,000 to 10,000 unprecedented ailments impacting individuals, of which a few hundred have any treatment. Further, the rising number of captivating diseases is adding to the advancement of the immunoglobulin market area.

Market Segmentation

The Market segments of Plasma Fractionation, based on product type, include immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others.

The Plasma Fractionation Market based on Application is classified into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others. Based on an end-user the market is segmented into hospitals and clinics, clinical research laboratories, academic institutes, and others.

Regional Insights

The North American plasma fractionation market represented the biggest market share in 2022. This is because of the rising pervasiveness of different hereditary sicknesses, the developing geriatric populace, and expanding medical care use in the region. The high commonness of Alzheimer's illness and the viability of the plasma fractionation item in the treatment support the market development over the gauge period. Europe plasma fractionation market represents the second-biggest market share because of the rising predominance of immunodeficiency and draining issues in the region and expanding interests in these frameworks.

The Asia-Pacific plasma fractionation market is supposed to develop at a critical offer from 2023 to 2032. This is because of an expansion out in the open and confidential subsidizing for innovative work, great unofficial laws, expanded utilization of immunoglobulins, rising commonness of target illnesses with a maturing populace with blood-related sicknesses, and rising plasma-based therapy reception in the Asia-Pacific region.

The Rest of the World is fragmented into the Center East, Africa, and Latin America. plasma fractionation market in the previously mentioned regions is probably going to observe development because of the commonness of immune system illnesses in the regions. In addition, The Assembled Bedouin Emirates (UAE), Saudi Arabia, and South Africa are the 3 significant nations in the MEA.

Major Players

Key Companies in the market of Plasma Fractionation are CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), Hualan Bio (China), Mitsubishi Tanabe (Japan), Takeda Pharmaceutical (Japan), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), LFB Group (France), and Biotest AG (Germany).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1.1 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE
• 1.1.2 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION
• 1.1.3 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER
• 1.1.4 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 SCOPE OF THE STUDY
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 RESEARCH PROCESS
• 3.2 PRIMARY RESEARCH
• 3.3 SECONDARY RESEARCH
• 3.4 MARKET SIZE ESTIMATION
• 3.5 TOP DOWN & BOTTOM-UP APPROACH
• 3.6 FORECAST MODEL
• 3.7 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

• 4.1 DRIVERS
  • 4.1.1 GROWING USE OF IMMUNOGLOBULINS FOR VARIOUS THERAPEUTIC AREA
  • 4.1.2 DEMAND FOR PLASMA DERIVED MEDICINAL PRODUCTS DRIVES THE MARKET GROWTH
  • 4.1.3 DRIVER IMPACT ANALYSIS
• 4.2 RESTRAINTS
  • 4.2.1 EMERGENCE OF RECOMBINANT THERAPIES AS AN ALTERNATIVE TO PLASMA DERIVED MEDICINES RESTRAINTS THE MARKET GROWTH
  • 4.2.2 RESTRAINT IMPACT ANALYSIS
• 4.3 OPPORTUNITIES
  • 4.3.1 LAUNCH OF NEW TECHNOLOGIES BY KEY PLAYERS TO AUGMENT MARKET GROWTH

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY CHAIN ANALYSIS
  • 5.1.1 RAW APPLICATIONS
  • 5.1.2 MANUFACTURES
  • 5.1.3 DISTRIBUTION
  • 5.1.4 END USER
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 MAJOR COLD CHAIN PRODUCTS/DEVICES IN THE PLASMA FRACTIONATION MARKET
• 5.4 IMPACT OF COVID-19 ON THE GLOBAL PLASMA FRACTIONATION MARKET
  • 5.4.1 IMPACT ON SUPPLY CHAIN
  • 5.4.2 IMPACT ON PRODUCTION
  • 5.4.3 IMPACT ON REGIONS
  • 5.4.4 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS
  • 5.4.5 IMPACT ON PRICING

6 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE

• 6.1 OVERVIEW
• 6.2 IMMUNOGLOBULIN
  • 6.2.1 Intravenous Immunoglobulins
  • 6.2.2 Subcutaneous Immunoglobulins
  • 6.2.3 Others
• 6.3 COAGULATION FACTOR CONCENTRATES
  • 6.3.1 Factor VIII
  • 6.3.2 Factor IX
  • 6.3.3 Von Willebrand Factor
  • 6.3.4 Prothrombin Complex Concentrate
  • 6.3.5 Fibrinogen Concentrates
  • 6.3.6 Factor XIII
• 6.4 ALBUMIN
• 6.5 PROTEASE INHIBITORS
• 6.6 OTHERS

7 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 IMMUNOLOGY
• 7.3 NEUROLOGY
• 7.4 HEMATOLOGY
• 7.5 CRITICAL CARE
• 7.6 PULMONOLOGY
• 7.7 RHEUMATOLOGY
• 7.8 HEMATO-ONCOLOGY
• 7.9 OTHERS

8 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS & CLINICS
• 8.3 CLINICAL RESEARCH LABORATORIES
• 8.4 ACADEMIC INSTITUTES
• 8.5 OTHERS

9 GLOBAL PLASMA FRACTIONATION, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 ITALY
  • 9.3.4 SPAIN
  • 9.3.5 UK
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 LATIN AMERICA
  • 9.5.2 MIDDLE EAST
  • 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 COMPETITIVE OVERVIEW
• 10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL PLASMA FRACTIONATION MARKET
• 10.3 COMPETITIVE BENCHMARKING

11 COMPANY PROFILES

• 11.1 CSL BEHRING
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 GRIFOLS THERAPEUTICS
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BAXTER INTERNATIONAL INC.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 MITSUBISHI TANABE
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 TAKEDA PHARMACEUTICAL
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 OCTAPHARMA AG
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 HUALAN BIO
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
• 11.8 KEDRION S.P.A
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
• 11.9 LFB GROUP
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
• 11.10 BIOTEST AG
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES